Literature DB >> 11228211

Increased serum FSH in female fragile X premutation carriers with either regular menstrual cycles or on oral contraceptives.

R D Hundscheid1, D D Braat, L A Kiemeney, A P Smits, C M Thomas.   

Abstract

Fragile X premutations are known to be a risk factor for diminished ovarian function at a relatively young age. We studied endocrine profiles of female fragile X family members (n = 79) at risk of premature ovarian failure (POF). Of these 79 women aged <40 years, 45 had menstrual cycles, and 34 were using oral contraceptives. Of the women with menstrual cycles, the premutation carriers had higher serum FSH concentrations than women who were not carrying the premutation. Even premutation carriers with regular cycles showed increased serum FSH concentrations. Moreover, premutation carriers using oral contraceptives also demonstrated increased serum FSH concentrations. Irrespective of whether oral contraceptives were used, a serum FSH concentration of > or =15 IU/l was more common in the premutation carriers than in the other women. One premutation carrier using oral contraceptives had a serum FSH concentration of >40 IU/l, the threshold that defines POF. We confirmed that premutation carriers with menstrual cycles demonstrate premature ovarian dysfunction. However, we also found endocrine signs of unrecognized ovarian dysfunction in premutation carriers using oral contraceptives, despite endocrine alterations by oral contraceptives. Premutation carriers may have a poorer prognosis for future pregnancy, either achieved spontaneously or by assisted reproductive technology. We recommend that premutation carriers should be counselled not to wait too long if they wish to start a family.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11228211     DOI: 10.1093/humrep/16.3.457

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  21 in total

1.  Intra-individual stability over time of standardized anti-Mullerian hormone in FMR1 premutation carriers.

Authors:  M A Spath; T B Feuth; E G Allen; A P T Smits; H G Yntema; A Geurts van Kessel; D D M Braat; S L Sherman; C M G Thomas
Journal:  Hum Reprod       Date:  2011-05-15       Impact factor: 6.918

Review 2.  Fragile X-associated disorders: a clinical overview.

Authors:  Anne Gallagher; Brian Hallahan
Journal:  J Neurol       Date:  2011-07-12       Impact factor: 4.849

Review 3.  Implications of the FMR1 Premutation for Children, Adolescents, Adults, and Their Families.

Authors:  Anne Wheeler; Melissa Raspa; Randi Hagerman; Marsha Mailick; Catharine Riley
Journal:  Pediatrics       Date:  2017-06       Impact factor: 7.124

4.  FMR1 repeat sizes in the gray zone and high end of the normal range are associated with premature ovarian failure.

Authors:  Karla L Bretherick; Margo R Fluker; Wendy P Robinson
Journal:  Hum Genet       Date:  2005-06-02       Impact factor: 4.132

5.  Does the presence of AGG interruptions within the CGG repeat tract have a protective effect on the fertility phenotype of female FMR1 premutation carriers?

Authors:  M Friedman-Gohas; M Kirshenbaum; A Michaeli; N Domniz; S Elizur; H Raanani; R Orvieto; Y Cohen
Journal:  J Assist Reprod Genet       Date:  2020-02-24       Impact factor: 3.412

6.  Fragile X-associated primary ovarian insufficiency: evidence for additional genetic contributions to severity.

Authors:  Jessica Ezzell Hunter; Michael P Epstein; Stuart W Tinker; Krista H Charen; Stephanie L Sherman
Journal:  Genet Epidemiol       Date:  2008-09       Impact factor: 2.135

7.  Recommendations from multi-disciplinary focus groups on cascade testing and genetic counseling for fragile X-associated disorders.

Authors:  Allyn McConkie-Rosell; Liane Abrams; Brenda Finucane; Amy Cronister; Louise W Gane; Sarah M Coffey; Stephanie Sherman; Lawrence M Nelson; Elizabeth Berry-Kravis; David Hessl; Sufen Chiu; Natalie Street; Ajay Vatave; Randi J Hagerman
Journal:  J Genet Couns       Date:  2007-05-12       Impact factor: 2.537

Review 8.  The fragile-X premutation: a maturing perspective.

Authors:  Paul J Hagerman; Randi J Hagerman
Journal:  Am J Hum Genet       Date:  2004-03-29       Impact factor: 11.025

9.  Altered hypothalamus-pituitary-adrenal gland axis regulation in the expanded CGG-repeat mouse model for fragile X-associated tremor/ataxia syndrome.

Authors:  J R Brouwer; E Severijnen; F H de Jong; D Hessl; R J Hagerman; B A Oostra; R Willemsen
Journal:  Psychoneuroendocrinology       Date:  2008-05-12       Impact factor: 4.905

Review 10.  Unstable mutations in the FMR1 gene and the phenotypes.

Authors:  Danuta Loesch; Randi Hagerman
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.